Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuki Matsui

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Diabetology International|January 4, 2019
Negative effect of a previous diagnosis of diabetes on quality of life in a Japanese population: The Gifu Diabetes StudyYukiko Nonoyama, Mayumi Yamamoto, Shino Oba, et al.
Journal of Pharmacological Sciences|March 2, 2011
SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activityTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
Biological & Pharmaceutical Bulletin|March 1, 2021
Effects of Bepridil and Pimozide, Existing Medicines Capable of Blocking T-Type Ca<sup>2+</sup> Channels, on Visceral Pain in MiceMaho Tsubota, Kazuki Matsui, Saaya Fukushi, et al.
Pharmacology|February 4, 2012
Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated ratsTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2015
In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinibYasuhiro Tsume, Susumu Takeuchi, Kazuki Matsui, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 13, 2021
Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacyKazuki Matsui, Tomoya Nakagawa, Tomonori Okumura, et al.
International Journal of Pharmaceutics|December 23, 2022
Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokineticsKazuki Matsui, Katsuki Nakamichi, Masatoshi Nakatani, et al.
Journal of Cardiovascular Pharmacology|January 14, 2012
SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in ratsTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2007
RNAi gene silencing using cerasome as a viral-size siRNA-carrier free from fusion and cross-linkingKazuki Matsui, Yoshihiro Sasaki, Takayoshi Komatsu, et al.
European Journal of Pharmacology|September 27, 2005
Reduction of myocardial infarct size by SM-197378, a novel Na+/H+ exchange inhibitor, in rabbitsKazuto Yamada, Kazuki Matsui, Shoji Ogawa, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Diabetology International|January 4, 2019
Negative effect of a previous diagnosis of diabetes on quality of life in a Japanese population: The Gifu Diabetes StudyYukiko Nonoyama, Mayumi Yamamoto, Shino Oba, et al.
Journal of Pharmacological Sciences|March 2, 2011
SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activityTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
Biological & Pharmaceutical Bulletin|March 1, 2021
Effects of Bepridil and Pimozide, Existing Medicines Capable of Blocking T-Type Ca<sup>2+</sup> Channels, on Visceral Pain in MiceMaho Tsubota, Kazuki Matsui, Saaya Fukushi, et al.
Pharmacology|February 4, 2012
Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated ratsTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2015
In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinibYasuhiro Tsume, Susumu Takeuchi, Kazuki Matsui, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 13, 2021
Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacyKazuki Matsui, Tomoya Nakagawa, Tomonori Okumura, et al.
International Journal of Pharmaceutics|December 23, 2022
Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokineticsKazuki Matsui, Katsuki Nakamichi, Masatoshi Nakatani, et al.
Journal of Cardiovascular Pharmacology|January 14, 2012
SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in ratsTetsuro Nariai, Katsuya Fujita, Masaya Mori, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2007
RNAi gene silencing using cerasome as a viral-size siRNA-carrier free from fusion and cross-linkingKazuki Matsui, Yoshihiro Sasaki, Takayoshi Komatsu, et al.
European Journal of Pharmacology|September 27, 2005
Reduction of myocardial infarct size by SM-197378, a novel Na+/H+ exchange inhibitor, in rabbitsKazuto Yamada, Kazuki Matsui, Shoji Ogawa, et al.
Pageof 5